See more : Top Form International Limited (0333.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Nuvation Bio Inc. (NUVB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nuvation Bio Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- BeMap, Inc. (4316.T) Income Statement Analysis – Financial Results
- Belo Sun Mining Corp (BSXGF) Income Statement Analysis – Financial Results
- Kaname Kogyo Co.,Ltd. (6566.T) Income Statement Analysis – Financial Results
- 12 ReTech Corporation (RETC) Income Statement Analysis – Financial Results
- Silver Fields Resources Inc. (SFRFF) Income Statement Analysis – Financial Results
Nuvation Bio Inc. (NUVB)
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 222.00K | 484.00K | 368.00K | 103.00K | 0.00 | 0.00 |
| Gross Profit | -222.00K | -484.00K | -368.00K | -103.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 71.29M | 87.82M | 69.04M | 32.60M | 25.11M | 482.67K |
| General & Administrative | 26.83M | 31.92M | 24.28M | 10.95M | 6.59M | 509.33K |
| Selling & Marketing | 1.70M | 0.00 | 0.00 | 0.00 | 400.00 | 0.00 |
| SG&A | 28.53M | 31.92M | 24.28M | 10.95M | 6.99M | 509.33K |
| Other Expenses | 0.00 | -872.00K | -644.00K | -271.00K | 0.00 | 0.00 |
| Operating Expenses | 99.82M | 119.73M | 93.32M | 43.55M | 32.18M | 992.00K |
| Cost & Expenses | 99.82M | 119.73M | 93.32M | 43.55M | 32.18M | 992.00K |
| Interest Income | 24.61M | 7.45M | 2.96M | 1.95M | 1.37K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 222.00K | 484.00K | 368.00K | 103.00K | 13.00K | 992.00K |
| EBITDA | -99.60M | -119.54M | -89.35M | -43.45M | -32.09M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -99.82M | -119.73M | -93.32M | -43.55M | -32.10M | -992.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 24.02M | 15.54M | 6.47M | 1.89M | -1.45M | 0.00 |
| Income Before Tax | -75.80M | -104.20M | -86.85M | -41.66M | -33.55M | -992.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -15.54M | -7.11M | -2.16M | 0.00 | 0.00 |
| Net Income | -75.80M | -88.66M | -79.73M | -39.50M | -33.55M | -992.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.35 | -0.41 | -0.40 | -0.40 | -0.16 | -0.01 |
| EPS Diluted | -0.35 | -0.41 | -0.40 | -0.40 | -0.16 | -0.01 |
| Weighted Avg Shares Out | 218.88M | 216.72M | 197.89M | 97.53M | 206.67M | 80.99M |
| Weighted Avg Shares Out (Dil) | 218.88M | 216.72M | 197.89M | 97.53M | 206.67M | 80.99M |
Nuvation Bio Announces Departure of Chief Financial Officer
Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
Nuvation: Cash Is King, Science Is An Afterthought
Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
The 7 Worst Stocks to Buy Now
FDA Institutes Partial Hold On Nuvation Bio's Early-Stage Solid Tumor Trial - Read Why
Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate
FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors
Why Nuvation Bio Shares Are Rising
Nuvation Bio Appoints David C. Hanley, Ph.D.
Source: https://incomestatements.info
Category: Stock Reports